NCT00052949View on ClinicalTrials.gov

Imatinib Mesylate in Treating Patients With Recurrent Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

91

Participants

Timeline

Start Date

May 31, 2003

Primary Completion Date

October 31, 2007

Conditions
Recurrent Small Cell Lung Cancer
Interventions
DRUG

imatinib mesylate

Given orally

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

55905

North Central Cancer Treatment Group, Rochester

All Listed Sponsors
collaborator

Cancer and Leukemia Group B

NETWORK

lead

National Cancer Institute (NCI)

NIH

NCT00052949 - Imatinib Mesylate in Treating Patients With Recurrent Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter